We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors.
- Authors
Dajti, Gerti; Serra, Margherita; Cisternino, Giovanni; Ceccarelli, Claudio; Pellegrini, Alice; Melina, Marica; Leo, Antonio De; Santini, Donatella; Taffurelli, Mario; Zanotti, Simone
- Abstract
Purpose The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer
- Subjects
BREAST cancer prognosis; PROGESTERONE; IMMUNOPHENOTYPING; RESEARCH funding; BREAST tumors; RETROSPECTIVE studies; IMMUNOHISTOCHEMISTRY; GENE expression; PROGRESSION-free survival; CONFIDENCE intervals; GENETIC mutation
- Publication
Oncologist, 2024, Vol 29, Issue 5, p384
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad309